FrancophonIA/ELRC3.0 huggingface dataset:
English: Composite Matrix (Polyglactin 910 and oxidised regenerated cellulose) Arginine hydrochloride
Slovenian: Pomožne snovi: kompozitni matriks (poliglaktin 910 in oksidirana regenerirana celuloza) argininijev klorid glicin natrijev klorid natrijev citrat kalcijev klorid humani albumin manitol natrijev acetat
English: EVARREST should only be used in a single layer with an overlap of approximately 1 to 2 cm onto non-bleeding tissue to help it stick to the bleeding area.
Slovenian: Zdravilo EVARREST se sme uporabiti samo v enem sloju, da ustrezno pokrije celotno krvaveče mesto in da sega približno 1 cm do 2 cm na nekrvaveče tkivo, kar pripomore k sprijetju na krvaveče mesto.
English: Discard damaged packages.
Slovenian: V paketu sta 2 matriksa.
English: Pack size of 1 and as sealant matrices which are 5.1 cm x 10.2 cm in size, Pack size of 2.
Slovenian: V paketu sta 2 matriksa z lepilom za tkiva velikosti 5,1 cm x 10,2 cm.
English: EVARREST should only be used in a single layer, with an overlap of approximately 1 to 2 cm onto non-bleeding tissue, to assist with adherence to the wound site.
Slovenian: Zdravilo EVARREST se sme uporabiti samo v enem sloju, da ustrezno pokrije celotno krvaveče mesto in da sega približno 1 cm do 2 cm na nekrvaveče tkivo, kar pripomore k sprijetju na mesto rane.
English: (tube) - sealing surgical repairs to the intestines.
Slovenian: Zdravilo s poškodovano ovojnino zavrzite.
English: Keep out of sight and reach of children.
Slovenian: Shranjujte nedosegljivo otrokom!
English: The active side is powdery in appearance.
Slovenian: Stran z zdravilno učinkovino je videti prahasta.
English: Accumulation of fluid in the pancreas: the frequency was uncommon (may affect up to 1 in 100 people).
Slovenian: Kopičenje tekočine v trebušni slinavki; pogostnost je bila občasna (lahko se pojavi pri največ 1 od 100 bolnikov).
English: During surgery (operative haemorrhage); the frequency was uncommon (may affect up to 1 in 100 people).
Slovenian: Med kirurškim posegom (medoperativna krvavitev); pogostnost je bila občasna (lahko se pojavi pri največ 1 od 100 bolnikov).
English: EVARREST must be kept out of the sight and reach of children.
Slovenian: Zdravilo EVARREST shranjujte nedosegljivo otrokom!
English: EXPIRY DATE
Slovenian: Občasni Občasni
English: Name and address of the manufacturer(s) responsible for batch release Omrix Biopharmaceuticals N.V.
Slovenian: Ime in naslov izdelovalca (izdelovalcev), odgovornega (odgovornih) za sproščanje serij
English: Bottle (HDPE)
Slovenian: Peroralna uporaba Plastenka (HDPE)
English: EU (MA) Number Invented Name
Slovenian: EU številka Ime Jakost Farmacevtska oblika
English: 1.5 g 20 sachets Meat and offal: 3 days
Slovenian: V krmno mešanico Vrečke (papir/PE/a lu/PE),
English: Outcome of a procedure under Article 34 of Directive 2001/82/EC (EMEA/V/A/123)
Slovenian: Izid postopka v skladu s členom 34 Direktive 2001/82/ES (EMEA/V/A/123)
English: 5 October 2017
Slovenian: 5. oktober 2017
English: The European Commission issued a decision on 5 October 2017.
Slovenian: Evropska komisija je sklep izdala 5. oktobra 2017.
English: Lincocin is authorised in the EU via national procedures.
Slovenian: Zdravilo Lincocin je bilo v EU odobreno po nacionalnih postopkih.
English: Why was Lincocin reviewed?
Slovenian: Zakaj je bilo zdravilo Lincocin pregledano?
English: Lincocin (and associated names, such as Lincocine poudre soluble and Albiotic Pulver 400 mg/g) is marketed in Belgium, Denmark, France, Germany, Hungary, Ireland, Poland and United Kingdom.
Slovenian: Zdravilo Lincocin (in povezana imena, kot sta Lincocine poudre soluble in Albiotic Pulver 400 mg/g) se trži v Belgiji, na Danskem, v Franciji, v Nemčiji, na Madžarskem, Irskem, Poljskem in v Združenem kraljestvu.
English: On 13 July 2017, the European Medicines Agency (the Agency) completed a review of Lincocin.
Slovenian: Evropska agencija za zdravila (agencija) je 13. julija 2017 zaključila pregled zdravila Lincocin.
English: Questions and answers on Lincocin and its associated names EMA/585749/2017
Slovenian: Vprašanja in odgovori v zvezi z zdravilom Lincocin in povezanimi imeni EMA/585749/2017
English: Questions and answers on Lincocin and its associated names
Slovenian: Vprašanja in odgovori v zvezi z zdravilom Lincocin in povezanimi imeni
English: What is Lincocin?
Slovenian: Kaj je zdravilo Lincocin?
English: Lincomycin is a lincosamide antibiotic which is produced by Streptomyces lincolnensis.
Slovenian: Linkomicin je linkozamidni antibiotik, ki ga proizvajajo bakterije družine Streptomyces lincolnensis.
English: The European Commission noted that there are divergences across Member States in the way the veterinary medicinal product can be used, as seen in the differences in the product information in the countries where Lincocin is marketed.
Slovenian: Evropska komisija je opozorila, da med državami članicami obstajajo razlike v načinu, kako se zdravilo za uporabo v veterinarski medicini lahko uporablja, kar se odraža v razlikah med povzetki glavnih značilnosti zdravila v državah, v katerih se zdravilo Lincocin trži.
English: Lincocin is indicated for the treatment and metaphylaxis of enzootic pneumonia caused by Mycoplasma hyopneumoniae in pigs and treatment and metaphylaxis of necrotic enteritis caused by Clostridium perfringens in chickens.
Slovenian: Zdravilo Lincocin je indicirano za zdravljenje in metafilakso enzootske pljučnice pri prašičih, ki jo povzroča bakterija Mycoplasma hyopneumoniae, ter zdravljenje in metafilakso nekrotskega enteritisa pri piščancih, ki ga povzroča bakterija Clostridium perfringens.
English: Lincocin is a veterinary medicinal product available as powder for oral solution and contains 400 mg lincomycin per gram of product.
Slovenian: Lincocin je zdravilo za uporabo v veterinarski medicini, ki je na voljo kot prašek za peroralno raztopino in vsebuje 400 mg linkomicina na gram zdravila.
English: Based on the evaluation of the currently-available data, the CVMP concluded that the product information for Lincocin and its associated names should be harmonised across the EU.
Slovenian: Odbor CVMP je na podlagi vrednotenja trenutno razpoložljivih podatkov zaključil, da je treba informacije o zdravilu za zdravilo Lincocin in povezana imena uskladiti po vsej EU.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that there is a need to harmonise the product information [summary of product characteristics (SPC), labelling and package leaflet] for Lincocin in the European Union (EU).
Slovenian: Odbor za zdravila za uporabo v veterinarski medicini (CVMP) pri agenciji je zaključil, da je treba uskladiti informacije o zdravilu (povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo) za zdravilo Lincocin v Evropski uniji (EU).
English: Consequently, the CVMP recommended that variations to the terms of the marketing authorisations for the aforementioned product are required in order to amend the product information accordingly.
Slovenian: je treba za ustrezno spremembo informacij o zdravilu spremeniti pogoje dovoljenj za promet z zgoraj navedenim zdravilom.
English: On 5 July 2016, the European Commission referred the matter to the CVMP in order to harmonise the product information for Lincocin (and associated names) in the EU.
Slovenian: Da bi Evropska komisija uskladila informacije o zdravilu Lincocin (in povezanih imenih) v EU, je 5. julija 2016 zadevo napotila na odbor CVMP.
English: Do not drive or use machines until this has worn off.
Slovenian: Ne vozite ali ne upravljajte strojev, dokler ta učinek ne mine.
English: How much to use see side 1
Slovenian: Koliko zdravila uporabiti <glejte 1. stran
English: In the case of overdose, appropriate monitoring and management of the patient should be implemented.
Slovenian: V primeru prevelikega odmerjanja je treba izvajati ustrezno spremljanje in vodenje bolnika.
English: Do not give this medicine to children under the ages of 3 years because there is no data to indicate that it is safe and work in children under 3 years.
Slovenian: Ne dajajte tega zdravila otrokom, mlajšim od 3 let, ker ni podatkov, ki bi kazali, da je zdravilo varno in da deluje pri otrocih, mlajših od 3 let.
English: Treatment may be maintained for up to four months, if considered necessary.
Slovenian: Zdravljenje lahko po potrebi traja do štiri mesece.
English: The recommended dose is one drop in the eye or eyes, twice a day, morning and evening.
Slovenian: Priporočeni odmerek je ena kapljica v oko ali oči dvakrat na dan, zjutraj in zvečer.
English: • If you use drops in both eyes, repeat the steps for your other eye.
Slovenian: • Če uporabljate kapljice v obeh očesih, ponovite te korake tudi na drugem očesu.
English: It works by reducing the intensity of the allergic reaction.
Slovenian: Deluje tako, da zmanjša jakost alergijske reakcije.
English: • If you are allergic (hypersensitive) to olopatadine or any of the other ingredients of this medicine (listed in section 6).
Slovenian: • če ste alergični (preobčutljivi) na olopatadin ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
English: Use this much unless your doctor tells you to do differently.
Slovenian: Uporabite toliko, razen če vam zdravnik predpiše drugače.
English: Do not put in any more drops until it's time for your next regular dose.
Slovenian: Kapljic ne vkapajte ponovno, dokler ne bo čas za naslednji redni odmerek.
English: Approximately 60-70% of the dose was recovered in the urine as active substance.
Slovenian: Približno 60 do 70 % odmerka je bilo izmerjenega v urinu v obliki zdravilne učinkovine.
English: The most frequent treatment-related adverse reaction was eye pain, reported at an overall incidence of 0.7%.
Slovenian: Najpogostejši z zdravljenjem povezan neželeni učinek so bile očesne bolečine, ki so bile prijavljene s splošno incidenco 0,7 %.
English: Approximately 4.5% of patients can be expected to experience adverse reactions associated with the use of Opatanol; however, only 1.6% of patients discontinued from the clinical studies due to these adverse reactions.
Slovenian: Pri približno 4,5 % bolnikov lahko pričakujemo pojav neželenih učinkov, povezanih z uporabo zdravila Opatanol, vendar je zaradi teh neželenih učinkov v kliničnih študijah prenehalo sodelovati le 1,6 % bolnikov.
English: Do not use a double dose to make up for the one missed.
Slovenian: Ne uporabite dvojnega odmerka, da bi nadomestili izpuščenega.
English: The following adverse reactions have been reported during clinical studies and post-marketing data and are classified according to the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1000)very rare (<1/10,000) or not known (cannot be estimated from the available data).
Slovenian: Naslednji neželeni učinki, o katerih so poročali v kliničnih študijah in v obdobju trženja zdravila, so razvrščeni po pogostnosti v skladu z naslednjim dogovorom: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000) ali neznana pogostnost (je ni mogoče oceniti iz razpoložljivih podatkov).
English: You should throw away the bottle four weeks after you first opened it to prevent infections, and use a new bottle.
Slovenian: Kapalni vsebnik morate zavreči štiri tedne po tem, ko ste ga prvič odprli, da preprečite okužbe, in potem uporabite nov kapalni vsebnik.
English: The safety and efficacy of Opatanol in children aged under 3 years has not been established.
Slovenian: Varnost in učinkovitost zdravila Opatanol pri otrocih, mlajših od 3 let, še nista bili dokazani.
English: In vitro studies have shown that olopatadine did not inhibit metabolic reactions which involve cytochrome P-450 isozymes 1A2, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4.
Slovenian: Študije in vitro so pokazale, da olopatadin ne zavira presnovnih reakcij, v katerih sodelujejo izoencimi citokroma P450 1A2, 2C8, 2C9, 2C19, 2D6, 2E1 in 3A4.
English: Date of first authorisation: 17 May 2002 Date of latest renewal: 22 May 2007
Slovenian: Datum zadnjega podaljšanja: 22. maj 2007
English: Do not use Opatanol in children under the age of 3 years.
Slovenian: Zdravila Opatanol ne uporabljajte pri otrocih, mlajših od 3 let.
English: Use a single drop as soon as you remember, and then go back to your regular dosing routine.
Slovenian: Vkapajte eno kapljico takoj, ko se spomnite, potem pa nadaljujte z rednim odmerjanjem.
English: In clinical studies involving 1680 patients, Opatanol was administered one to four times daily in both eyes for up to four months as monotherapy or adjunctive therapy to loratadine 10 mg.
Slovenian: V kliničnih študijah pri 1680 bolnikih so zdravilo Opatanol vkapali v obe očesi enkrat do štirikrat na dan v času do štirih mesecev, kot monoterapijo ali kot adjuvantno terapijo ob loratadinu v odmerku 10 mg.
English: The dose is one drop of Opatanol in the conjunctival sac of the affected eye(s) twice daily (8 hourly).
Slovenian: Odmerek je ena kapljica zdravila Opatanol v veznično vrečko prizadetega očesa (oči) dvakrat na dan (na 8 ur).
English: If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
Slovenian: Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom, pred uporabo tega zdravila.
English: Olopatadine is a potent selective antiallergic/antihistaminic agent that exerts its effects through multiple distinct mechanisms of action.
Slovenian: Olopatadin je močno selektivno protialergijsko zdravilo/antihistaminik, ki svoje učinke doseže preko več različnih mehanizmov delovanja.
English: If signs of serious reactions or hypersensitivity occur, discontinue the use of this treatment.
Slovenian: Če se pojavijo znaki resne reakcije ali preobčutljivosti, mora bolnik prenehati z uporabo tega zdravila.
English: Summary of safety profile
Slovenian: Povzetek profila varnosti zdravila
English: This medicine contains 0.5 mg benzalkonium chloride in each 5 ml which is equivalent to 0.1 mg/ml.
Slovenian: To zdravilo vsebuje 0,5 mg benzalkonijevega klorida v 5 ml, kar je enako 0,1 mg/ml.
English: If you stop using Opatanol Do not stop using this medicine without first speaking to your doctor.
Slovenian: Če ste prenehali uporabljati zdravilo Opatanol Tega zdravila ne smete prenehati uporabljati, ne da bi se prej posvetovali z zdravnikom.
English: Olopatadine is not recommended during pregnancy and in women of childbearing potential not using contraception.
Slovenian: Uporaba olopatadina ni priporočljiva med nosečnostjo in pri ženskah v rodni dobi, ki ne uporabljajo kontracepcije.
English: Opatanol may be used in paediatric patients three years of age and older at the same dose as in adults.
Slovenian: Zdravilo Opatanol se pri pediatričnih bolnikih, starih tri leta in več, lahko uporablja v istem odmerku kot pri odraslih.
English: If you are using other eye drops or eye ointment medicines, leave at least 5 minutes between each medicine.
Slovenian: Če uporabljate tudi druge kapljice za oko ali mazila za oko, počakajte najmanj 5 minut med uporabo vsakega zdravila.
English: Prolongation of the QTc interval in dogs was observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.
Slovenian: Podaljšanje QTc intervala pri psih so opažali le pri izpostavljenostih, ki so bile zadosti večje od največje izpostavljenosti za človeka, kar pomeni, da so le malo pomembne za klinično uporabo zdravila.
English: How to use Opatanol (continued)
Slovenian: Kako uporabljati zdravilo Opatanol (nadaljevanje)
English: What OPATANOL is and what it is used for
Slovenian: Kaj je zdravilo Opatanol in za kaj ga uporabljamo
English: Some materials (allergens) like pollens, house dust or animal fur may cause allergic reactions resulting in itching, redness as well as swelling of the surface of your eye.
Slovenian: Nekatere snovi (alergeni), kot so cvetni prah, hišni prah ali živalska dlaka, lahko povzročijo alergijske reakcije s srbenjem, rdečino in otekanjem površine očesa.
English: However, if it is almost time for your next dose, skip the missed dose before going back to your regular dosing routine.
Slovenian: Vendar, če je že skoraj čas za naslednji odmerek, preskočite izpuščeni odmerek in nadaljujte z rednim režimom odmerjanja.
English: In case of concomitant therapy with other topical ocular medicines, an interval of five minutes should be allowed between successive applications.
Slovenian: V primeru sočasne terapije z drugimi topikalnimi očesnimi zdravili mora med zaporednimi aplikacijami zdravil preteči 5 minut.
English: These concentrations are 50-to 200-fold lower than those following well tolerated oral doses.
Slovenian: Te koncentracije so 50 do 200-krat manjše od tistih po peroralnih odmerkih, ki so jih bolniki še dobro prenašali.
English: It antagonises histamine (the primary mediator of allergic response in humans) and prevents histamine induced inflammatory cytokine production by human conjunctival epithelial cells.
Slovenian: Je antagonist histamina (primarnega mediatorja alergijskega odziva pri človeku) in preprečuje s histaminom povzročeno tvorbo vnetnih citokinov v človeških vezničnih epitelijskih celicah.
English: Shelf-life after first opening
Slovenian: Rok uporabnosti po prvem odprtju
English: Available data in animals have shown excretion of olopatadine in milk following oral administration (for details see section 5.3).
Slovenian: Razpoložljivi podatki pri živalih kažejo na izločanje olopatadina v mleko po peroralni uporabi (za podrobnosti glejte poglavje 5.3).
English: 5 ml opaque low density polyethylene bottles with polypropylene screw caps (DROP-TAINER).
Slovenian: 5 ml neprozorni kapalni vsebniki iz polietilena nizke gostote s polipropilensko navojno zaporko (DROP-TAINER).
English: Other medicines and Opatanol
Slovenian: Druga zdravila in zdravilo Opatanol
English: A 5 mg oral dose was administered twice-daily for 2.5 days to 102 young and elderly male and female healthy volunteers with no significant prolongation of QTc interval compared to placebo.
Slovenian: 5 mg peroralni odmerek so dajali 102 mladim in starejšim zdravim prostovoljcem moškega in ženskega spola, in sicer dvakrat na dan 2,5 dni in ni bilo značilnega podaljšanja QTc intervala v primerjavi s tistimi, ki so prejemali placebo.
English: However, no dosage adjustment is expected to be necessary in hepatic or renal impairment (see section 5.2).
Slovenian: Vendar v primeru ledvične ali jetrne okvare ni pričakovati, da bi bila potrebna prilagoditev odmerka (glejte poglavje 5.2).
English: From oral pharmacokinetic studies, the half-life of olopatadine in plasma was approximately eight to 12 hours, and elimination was predominantly through renal excretion.
Slovenian: V peroralnih študijah farmakokinetike je bila razpolovna doba olopatadina v plazmi približno 8 do 12 ur, zdravilo pa se je izločalo predvsem preko ledvic.
English: Accidental ingestion of the entire contents of a bottle of Opatanol would deliver a maximum systemic exposure of 5 mg olopatadine.
Slovenian: Nezgodno zaužitje celotne vsebine kapalnega vsebnika zdravila Opatanol bi vodilo do največje sistemske izpostavljenosti 5 mg olopatadina.
English: The preservative in Opatanol, benzalkonium chloride, may be absorbed by soft contact lenses and may change the colour of the contact lenses.
Slovenian: Konzervans v zdravilu Opatanol, benzalkonijev klorid, se lahko absorbira v mehke kontaktne leče in lahko spremeni barvo kontaktnih leč.
English: Olopatadine in the form of eye drops (Opatanol) has not been studied in patients with renal or hepatic disease.
Slovenian: Olopatadina v obliki kapljic za oko (Opatanol) še niso raziskovali pri bolnikih z ledvično ali jetrno boleznijo.
English: Studies in animals have shown reduced growth of nursing pups of dams receiving systemic doses of olopatadine well in excess of the maximum level recommended for human ocular use.
Slovenian: Študije na živalih so pokazale zmanjšano rast dojenih mladičev samic, ki so prejemale sistemske odmerke olopatadina, precej večje od največjega priporočenega odmerka za okularno uporabo pri človeku.
English: These results indicate that olopatadine is unlikely to result in metabolic interactions with other concomitantly administered active substances.
Slovenian: Ti izsledki nakazujejo, da je malo verjetno, da bi olopatadin povzročil presnovne interakcije z drugimi sočasno uporabljenimi učinkovinami.
English: Data from in vitro studies suggest that it may act on human conjunctival mast cells to inhibit the release of pro-inflammatory mediators.
Slovenian: Podatki iz študij in vitro kažejo, da lahko deluje na človeške mastocite v veznici in zavira sproščanje vnetnih mediatorjev.
English: As with any eye drop, temporary blurred vision or other visual disturbances may affect the ability to drive or use machines.
Slovenian: Kot pri vseh kapljicah za oko lahko začasno zamegljen vid ali druge motnje vida vplivajo na sposobnost bolnika za vožnjo ali upravljanje s stroji.
English: What Opatanol looks like and contents of the pack Opatanol is a clear and colourless liquid (a solution) supplied in a pack containing either one 5 ml bottle or three 5 ml plastic bottles with screw caps.
Slovenian: Izgled zdravila Opatanol in vsebina pakiranja Opatanol je bistra in brezbarvna tekočina (raztopina), ki je na voljo v pakiranjih s 5 ml kapalnim vsebnikom ali s tremi 5 ml plastičnimi kapalnimi vsebniki z navojno zaporko.
English: The results indicate that a somewhat higher plasma concentration can be expected with Opatanol in this population.
Slovenian: Izsledki te študije kažejo, da lahko pri tej populaciji bolnikov pričakujemo nekoliko višje plazemske koncentracije zdravila Opatanol.
English: The range of peak steady-state olopatadine plasma concentrations (35 to 127 ng/ml) seen in this study represents at least a 70-fold safety margin for topical olopatadine with respect to effects on cardiac repolarisation.
Slovenian: Razpon največjih plazemskih koncentracij olopatadina v stanju dinamičnega ravnovesja (35 do 127 ng/ml), ki so ga ugotavljali v tej študiji, pomeni najmanj 70-kratni varnostni faktor za olopatadin pri topikalni uporabi glede na učinke na srčno repolarizacijo.
English: • Get the Opatanol bottle and a mirror.
Slovenian: • Vzemite kapalni vsebnik zdravila Opatanol in ogledalo.
English: What Opatanol contains - The active substance is olopatadine.
Slovenian: Kaj vsebuje zdravilo Opatanol - Učinkovina je olopatadin.
English: Studies comparing the pharmacokinetics of 10 mg oral doses of olopatadine in young (mean age 21 years) and elderly (mean age 74 years) showed no significant differences in the plasma concentrations (AUC), protein binding or urinary excretion of unchanged parent drug and metabolites.
Slovenian: Študije za primerjavo farmakokinetike 10 mg peroralnih odmerkov olopatadina pri mladih (srednja starost 21 let) in pri starostnikih (srednja starost 74 let) niso pokazale nobenih značilnih razlik v plazemski koncentraciji nespremenjene zdravilne učinkovine in njenih presnovkov (AUC), njihovi vezavi na beljakovine ali njihovem izločanju z urinom.
English: BOX OF 1 BOTTLE + BOX OF 3 BOTTLES
Slovenian: ŠKATLA Z 1 KAPALNIM VSEBNIKOM + ŠKATLA S 3 KAPALNIMI VSEBNIKI
English: • Hold the bottle, pointing down, between your thumb and middle finger.
Slovenian: • Kapalni vsebnik držite s palcem in sredincem, obrnjeno navzdol.
English: If you forget to use Opatanol
Slovenian: Če ste pozabili uporabiti zdravilo Opatanol
English: Now turn over.
Slovenian: Obrnite list.
English: Only use Opatanol in both eyes if your doctor told you to. Use it for as long as your doctor told you to.
Slovenian: Zdravilo Opatanol uporabljajte na obeh očeh le, če vam je zdravnik to predpisal.
English: If blurred vision occurs at instillation, the patient must wait until the vision clears before driving or using machinery.
Slovenian: Če po vkapanju kapljic nastopi zamegljen vid, mora bolnik počakati, da se mu vid zbistri, preden lahko spet vozi ali upravlja stroje.